Equities Analysts Set Expectations for Lantheus Q3 Earnings

Lantheus Holdings, Inc. (NASDAQ:LNTH) – Equities research analysts at Brookline Cap M issued their Q3 2026 EPS estimates for shares of Lantheus in a research note issued to investors on Wednesday, February 11th. Brookline Cap M analyst K. Dolliver forecasts that the medical equipment provider will earn $1.18 per share for the quarter. The consensus estimate for Lantheus’ current full-year earnings is $6.01 per share. Brookline Cap M also issued estimates for Lantheus’ Q4 2026 earnings at $1.38 EPS.

A number of other brokerages also recently weighed in on LNTH. Mizuho boosted their price target on Lantheus from $60.00 to $72.00 and gave the company an “outperform” rating in a report on Wednesday, December 17th. Weiss Ratings raised shares of Lantheus from a “sell (d+)” rating to a “hold (c-)” rating in a report on Tuesday, January 6th. Finally, Truist Financial boosted their price objective on shares of Lantheus from $80.00 to $82.00 and gave the company a “buy” rating in a research report on Thursday, December 18th. Five investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $78.00.

Lantheus Stock Up 2.1%

Shares of Lantheus stock opened at $68.72 on Friday. The business has a 50-day moving average price of $66.18 and a 200 day moving average price of $59.58. Lantheus has a fifty-two week low of $47.25 and a fifty-two week high of $111.29. The firm has a market cap of $4.56 billion, a P/E ratio of 28.87 and a beta of -0.08. The company has a quick ratio of 2.49, a current ratio of 2.67 and a debt-to-equity ratio of 0.51.

Institutional Investors Weigh In On Lantheus

Several large investors have recently made changes to their positions in the company. Stanley Laman Group Ltd. boosted its stake in Lantheus by 38.7% during the third quarter. Stanley Laman Group Ltd. now owns 79,686 shares of the medical equipment provider’s stock valued at $4,087,000 after buying an additional 22,229 shares in the last quarter. American Assets Inc. acquired a new stake in Lantheus in the 3rd quarter valued at about $872,000. Campbell & CO Investment Adviser LLC acquired a new stake in Lantheus in the 3rd quarter valued at about $2,184,000. Y Intercept Hong Kong Ltd bought a new position in shares of Lantheus during the 3rd quarter valued at about $3,866,000. Finally, Fox Run Management L.L.C. acquired a new position in shares of Lantheus in the 2nd quarter worth approximately $654,000. Institutional investors and hedge funds own 99.06% of the company’s stock.

Lantheus Company Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.